


Wnt Research

Developing novel cancer drugs to treat several metastasing cancer diseases originating in breast, colon, prostate and melanoma cancers.



Wnt-5a negative and positive tumour cells

Benefits:

Drug candidate Foxy-5 reduces metastases by 80%. Novel mechanisms of action: inhibiting cell motility and ER upregulation.

www.wntresearch.com

Development stage:

Completed pre-GLP phase preclinical studies

Market:

The current market for chemotherapies is estimated at US\$42 billion and is forecast to increase approximately 17% to US\$49 billion by 2012.

Intellectual property:

File worldwide in the following territories: EP, US, CA, CN, IN, AU and JP.

WntResearch pipeline drug candidates and the number of patients/year:

Clinical program	Substance	Patients	Market (MUSD)
ER-receptor negative breast cancer	Foxy-5	200.000	900
Breast cancer (low Wnt5-a)	Foxy-5	300.000	1100
Colon cancer (Metastatic)	Foxy-5	150.000	750
Prostate cancer (Metastatic)		120.000	600
Melanoma	Box-5	60.000	300
TOTAL:		830.000	3650

Contact:

Dr. Bert Junno, Lund University Technology Group, +46-707-772209, bert.junno@forskarpatent.com

Dr. Mikael Lindstam, Lund University Technology Group, +46-766-333699, mikael.lindstam@forskarpatent.com